Cross-tolerance between analgesia produced by xylazine and selective opioid receptor subtype treatments

European Journal of Pharmacology

Volumn 389, Issue 2-3, 2000, Pages 181-185

  Ware, Todd D ^a   Paul, Dennis ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

2 adrenoceptor; DAMGO; DPDPE; Opioid receptor subtype; Tyr W MIF 1; U50,488; Xylazine

Indexed keywords

3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE; ALPHA 2 ADRENERGIC RECEPTOR; DELTA OPIATE RECEPTOR; DELTORPHIN; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; ENKEPHALIN[2,5 DEXTRO PENICILLAMINE]; KAPPA OPIATE RECEPTOR; MORPHINE; MU OPIATE RECEPTOR; OPIATE AGONIST; OPIATE RECEPTOR; XYLAZINE; YOHIMBINE;

ANALGESIA; ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG CROSS TOLERANCE; DRUG RECEPTOR BINDING; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TAIL FLICK TEST;

3,4-DICHLORO-N-METHYL-N-(2-(1-PYRROLIDINYL)-CYCLOHEXYL)-BENZENEACETAMIDE, (TRANS)-ISOMER; ADRENERGIC ALPHA-AGONISTS; ANALGESIA; ANALGESICS, OPIOID; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOLERANCE; ENKEPHALIN, ALA(2)-MEPHE(4)-GLY(5)-; ENKEPHALIN, D-PENICILLAMINE (2,5)-; MALE; MICE; OLIGOPEPTIDES; RECEPTORS, ADRENERGIC, ALPHA-2; XYLAZINE; YOHIMBINE;

EID: 0034681439     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(99)00900-0     Document Type: Article

References (31)

1. Ben-Zvi Z., Graham C.E., Hurwitz A. Tolerance to effects of clonidine and morphine on sulfobromophthalein disposition in mice. Life Sci. 40:1987;1617-1623.
2. Bentley G.A., Newton S.H., Starr J. Studies on the antinociceptive action of alpha-agonist drugs and their interactions with opioid mechanisms. Br. J. Pharmacol. 7:1983;125-134.
3. D'Amour F.E., Smith D.L. A method for determining loss of pain sensation. J. Pharmacol. Exp. Ther. 72:1941;74-79.
4. Fairbanks C.A., Wilcox G.L. Spinal antinociceptive synergism between morphine and clonidine persists in mice made acutely or chronically tolerant to morphine. J. Pharmacol. Exp. Ther. 288:1999;1107-1116.
5. 2-adrenoceptors. Eur. J. Pharmacol. 298:1996;235-239.
6. Gistrak M.A., Paul D., Hahn E.F., Pasternak G.W. Pharmacological actions of a novel mixed opioid agonist/antagonist: naloxone benzoylhydrazone. J. Pharmacol. Exp. Ther. 251:1989;469-476.
7. Goudie A.J., Griffiths J.W. Behavioral factors in drug tolerance. Trends Pharmacol. Sci. 7:1986;192-196.
8. Haley T.J., McCormick W.G. Pharmacological effects produced by intracerebral injections of drugs in the conscious mouse. Br. J. Pharmacol. Chemother. 12:1957;12-15.
9. Heyman J.S., Mulvaney S.A., Mosberg H.I., Porreca F. Opioid delta receptor involvement in supraspinal and spinal antinociception in mice. Brain Res. 420:1987;100-107.
10. Heyman J.S., Williams C.I., Burks T.F., Mosberg H.I., Porreca F. Dissociation of opioid antinociception and central gastrointestinal propulsion in the mouse: studies with naloxonazine. J. Pharmacol. Exp. Ther. 245:1988;238-243.
11. Hsu W.H. Xylazine-induced delay of small intestinal transit in mice. Eur. J. Pharmacol. 83:1982;55-60.
12. Hylden J.L.K., Wilcox G.L. Intrathecal morphine in mice: a new technique. Eur. J. Pharmacol. 67:1980;313-316.
13. 6]enkephalin and naltrindole 5′-isothiocyanate: evidence for subtypes. J. Pharmacol. Exp. Ther. 257:1991;1069-1075.
14. Luttinger D., Ferrari R. Pharmacological analysis of alpha-2 adrenergic mechanisms in nociception and ataxia. J. Pharmacol. Exp. Ther. 232:1995;883-889.
15. 2]deltorphin II in mice: evidence for delta receptor subtypes. J. Pharmacol. Exp. Ther. 258:1991;583-587.
16. Millan M.J. κ-opioid receptors and antinociception. Trends Pharmacol. Sci. 11:1990;70-75.
17. Milne B., Cervenko F., Jhamandas K., Loomis C., Sutak M. Antinociception and tolerance to intrathecal morphine and norepinephrine infusion via implanted mini-osmotic pumps in the rat. Pain. 22:1985;165-172.
18. Mutlib A.E., Chui Y.C., Young L.M., Abbott F.S. Characterization of metabolites of xylazine produced in vivo and in vitro by LC/MS/MS and by GC/MS. Drug Metab. Dispos. 20:1992;840-848.
19. Paalzow G. Development of tolerance to the analgesic effect of clonidine in rats: cross-tolerance to morphine. Naunyn-Schmiedeberg's Arch. Pharmacol. 304:1978;1-4.
20. Paul D., Bodnar R.J., Gistrak M.A., Pasternak G.W. Different mu receptor subtypes mediate spinal and supraspinal analgesia in mice. Eur. J. Pharmacol. 168:1989;307-314.
21. Paul D., Levison J.A., Howard D.G., Pick C.G., Hahn E.F., Pasternak G.W. Naloxone benzoylhydrazone (NalBzoH) antinociception. J. Pharmacol. Exp. Ther. 255:1990;769-774.
22. 2-adrenoceptor agonists and receptor subtype selective opioid treatments. Eur. J. Pharmacol. 272:1995;111-114.
23. 2,5]enkephalin in the mouse. J. Pharmacol. Exp. Ther. 241:1987;393-398.
24. Portenoy R.K. Opioid tolerance and responsiveness: research findings and clinical observations. Gebhart G.F., Hammond D.L., Jensen T.S. Proceedings of the 7th World Congress on Pain. 1994;595-619 IASP, Seattle.
25. 2-adrenoceptor agonists. J. Neural Transm. 72:1988;1-9.
26. Roerig S.C., Fujimoto J.M. Multiplicative interaction between intrathecally and intracerebroventricularly administered mu opioid agonists but limited interactions between delta and kappa agonists for antinociception in mice. J. Pharmacol. Exp. Ther. 249:1989;762-768.
27. Roerig S.C., Lei S., Kitto K., Hylden J.K.L., Wilcox G.L. Spinal interactions between opioid and noradrenergic agonists in mice: multiplicativity involves delta and alpha-2 receptors. J. Pharmacol. Exp. Ther. 262:1992;365-374.
28. Stevens C.W. Perspectives on opioid tolerance from basic research: behavioural studies after spinal administration in rodents. Cancer Surv. 21:1994;25-98.
29. Stevens C.W., Monasky M.S., Yaksh T.L. Spinal infusion of opiate and alpha-2 agonists in rats: tolerance and cross-tolerance studies. J. Pharmacol. Exp. Ther. 244:1988;63-70.
30. Umans J.G., Inturrisi C.E. Pharmacodynamics of subcutaneously administered diacetylmorphine, 6-acetyl morphine and morphine in mice. J. Pharmacol. Exp. Ther. 218:1981;409-415.
31. Wigdor S., Wilcox G.L. Central and systemic morphine-induced antinociception: contribution of descending serotonergic and noradrenergic pathways. J. Pharmacol. Exp. Ther. 242:1987;90-95.